FDG-PET/CT Profile draft (Version 0.2) discussed

- Profile Section 9 (Analysis) focus of discussion
- Figures and equations deemed necessary for both protocol and Profile content
- Reminder that numerous stakeholders will be audience (physicians, equipment manufacturers, pharma, etc)
  - Protocol (i.e. use instructions) to assist clinicians by providing parameters to use in clinical trials and patient management
  - Profile (compliance details) to assist equipment and software vendors (e.g., provide standard methodology for extracting SUV from images)
- List of FDG-PET/CT core details discussed
- Feedback needed on core details for later incorporation into Profile document
- Claims to be mixture of table and narrative format
- Repositioning of Compliance details (Profile Section IV) discussed
- Provisional core detail template discussed
- Responsibility for all stakeholders needs to be obvious in Profile
- Level of “Acceptable” performance needs to be better defined; considered a debating point with manufacturers
- Protocol

Core issues/ details to be address in Profile

- SUV computations
- ROI computations
- Software version tracking
- QA/QC tracking
- Covariates
- Quantitative reporting
- Consistency issues
- Flexibility issues

Next steps:

- Feedback needed on core details for later incorporation into Profile document
- Dr Kinahan to develop draft of SUVmax details and definition (1 page) for group feedback and Profile incorporation; RSNA staff to circulate among group members for reference/ feedback
- Dr Perlman to forward updated sections 9 & 10 to Mr Buckler for Profile inclusion
- Dr Kong to follow-up with Dr Kinahan concerning UPICT/PET protocol writing group details
- Next call focus to be primarily Profile content, not format
- Next call scheduled for Friday, February 25, at 9 AM CST